Skip to Content

Drug Safety and Dementia

ABCD study team key publications

Sakel M, Boukouvalas A, Buono M et alDoes anticholinergics drug burden relate to global neuro-disability outcome measures and length of hospital stay? Brain Inj 2015;5:1-5. [Epub ahead of print].

Richardson K, Bennett K, Maidment I, et al. Use of medications with anti-cholinergic activity and self-reported injurious falls in the older aged community-dwelling population. J Am Geriatr Soc 2015 [Epub ahead of print].

Woehrling EK, Parri HR, Tse EHY, et al. A Predictive In Vitro Model of the Impact of Drugs with Anticholinergic Properties on Human Neuronal and Astrocytic Systems. PLoS ONE 2015;10:e0118786. doi:10.1371/journal.pone.0118786

Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 2014;:afu096. doi:10.1093/ageing/afu096

Peklar J, O’Halloran AM, Maidment ID, et al. Sedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years. J Am Med Dir Assoc [Epub ahead of print] doi:10.1016/j.jamda.2014.10.010

Myint PK, Fox C, Kwok CS, et al. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population studyAge Ageing 2014;:afu185. doi:10.1093/ageing/afu185

Campbell NL, Maidment I, Fox C, et al. The 2012 Update to the Anticholinergic Cognitive Burden Scale. J Am Geriatr Soc 2013;61:S1–232. doi:10.1111/jgs.12263

Cai X, Campbell N, Khan B, et al. Long-term anticholinergic use and the aging brain. Alzheimers Dement 2013;9(4):377-85. doi:10.1016/j.jalz.2012.02.005

Fox C, Richardson K, Maidment ID, et al. Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study. J Am Geriatr Soc 2011;59:1477–83. doi:10.1111/j.1532-5415.2011.03491.x

Fox C, Livingston G, Maidment ID, et al. The impact of anticholinergic burden in Alzheimer’s Dementia-the Laser-AD study. Age Ageing 2011;40:730–5. doi:10.1093/ageing/afr102

Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010;75:152–9. doi:10.1212/WNL.0b013e3181e7f2ab

Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008;4:311–20. doi:10.2217/1745509X.4.3.311

Maidment ID. Zaleplon for Insomnia. J Pharm Technol 2001;17:39–43. doi:10.1177/875512250101700202